# APBA Kısa Özet

The U.S. Food and Drug Administration (FDA) has granted approval to Lisraya (brepocitinib), a once‑daily oral tablet, as the first FDA‑approved therapy specifically indicated for dermatomyositis in adults. The decision rests on the results of a pivotal phase 3 randomized, double‑blind, placebo‑controlled trial (NCT05437263) that demonstrated statistically significant improvements in disease activity measures and a meaningful reduction in concomitant corticosteroid exposure. The approval introduces a novel oral JAK/TYK2 inhibition strategy for a condition that has historically required intravenous immunoglobulin, systemic steroids, or other parenteral immunosuppressants.

# Çalışma neyi araştırdı?

Dermatomyositis is a rare, immune‑mediated inflammatory myopathy characterized by proximal muscle weakness, characteristic skin findings, and a risk of interstitial lung disease. Existing therapeutic options are limited, and long‑term steroid use carries substantial morbidity. The phase 3 trial evaluated whether Lisraya, a selective JAK1/2 and TYK2 inhibitor, could provide disease control comparable to or better than standard care while allowing steroid tapering. The primary research question was: Does 30 mg of oral brepocitinib once daily improve the Total Improvement Score (TIS) at week 52 compared with placebo in adults with dermatomyositis? Secondary questions examined corticosteroid dose reduction, safety, and patient‑reported outcomes.

# Yöntem

  • Design: Multicenter, randomized, double‑blind, placebo‑controlled study.
  • Population: 241 adult participants (≥18 years) meeting established diagnostic criteria for dermatomyositis, with active disease despite stable background therapy.
  • Intervention: Lisraya 30 mg oral tablet once daily.
  • Comparator: Matching placebo tablet once daily.
  • Duration: 52 weeks of double‑blind treatment followed by an open‑label extension (data not included in the approval package).
  • Randomization & Blinding: Participants were allocated in a 1:1 ratio using a computer‑generated schedule; both participants and investigators remained blinded to assignment throughout the double‑blind phase.
  • Primary Endpoint: Proportion of participants achieving a predefined threshold on the Total Improvement Score (TIS) at week 52, a composite measure incorporating muscle strength, skin disease activity, physician global assessment, and functional indices.
  • Key Secondary Endpoints: (1) Mean change in TIS from baseline to week 52, (2) proportion achieving ≥20 % reduction in daily prednisone (or equivalent) dose, (3) safety profile including incidence of treatment‑emergent adverse events (TEAEs).
  • Statistical Analysis: Intent‑to‑treat population; binary outcomes analyzed with chi‑square tests, continuous outcomes with ANCOVA adjusting for baseline values; a two‑sided alpha of 0.05 was prespecified.

# Temel bulgular

  • Efficacy: The Lisraya group achieved a higher mean TIS at week 52 compared with placebo (exact values not disclosed in the press release but described as statistically significant). This indicates a broader and more robust clinical response across muscle, skin, and functional domains.
  • Corticosteroid Sparing: A significantly larger proportion of participants receiving Lisraya were able to reduce their corticosteroid dose by at least 20 % without disease flare, underscoring the steroid‑sparing potential of oral JAK/TYK2 inhibition.
  • Safety: The most frequently reported TEAEs were upper respiratory tract infection, headache, and fatigue. No new safety signals emerged relative to the known class‑effects of JAK inhibitors. Serious adverse events were rare and balanced between groups, though the press release truncated the full adverse‑event table.
  • Statistical Significance: Both the primary TIS endpoint and the corticosteroid‑reduction secondary endpoint met prespecified significance thresholds, satisfying the FDA’s efficacy criteria for approval.

# Bulgular ne anlama geliyor?

The trial demonstrates that oral inhibition of JAK1/2 and TYK2 can translate into clinically meaningful improvements for patients with dermatomyositis, a disease where oral options have been absent. By raising the Total Improvement Score, Lisraya appears to address both muscular and cutaneous manifestations simultaneously. The ability to taper steroids reduces exposure to the well‑documented long‑term complications of glucocorticoids, such as osteoporosis, diabetes, and infection risk. Moreover, the oral route simplifies administration, potentially improving adherence compared with intravenous therapies that require infusion centers.

# Klinik önem

  • Therapeutic Positioning: Lisraya offers clinicians an oral, disease‑modifying option that can be placed early in the treatment algorithm, especially for patients who are steroid‑dependent or who have contraindications to biologic infusions.
  • Monitoring: As with all JAK pathway inhibitors, baseline screening for latent infections (e.g., tuberculosis, hepatitis B) and periodic monitoring of complete blood counts, lipid panels, and liver enzymes are advisable. Patients with a history of cardiovascular disease or malignancy should be evaluated carefully before initiation.
  • Patient Selection: The trial enrolled adults with active disease; extrapolation to pediatric patients or those with overlapping connective‑tissue diseases is not supported by current data.
  • Shared Decision‑Making: Discussing the benefits of disease control and steroid reduction alongside the risk of infections and other class‑related adverse events will be essential for informed consent.

# Sınırlılıklar

  1. Duration of Follow‑up: The double‑blind phase lasted 52 weeks; long‑term safety and durability of response beyond one year remain unknown.
  2. Population Scope: Only adults with dermatomyositis were studied; efficacy in juvenile dermatomyositis, polymyositis, or other inflammatory myopathies has not been evaluated.
  3. Methodological Detail: The press release did not disclose granular information on randomization block size, allocation concealment, or the exact blinding procedures, limiting a full risk‑of‑bias assessment.
  4. Adverse‑Event Reporting: The summary truncated the adverse‑event table, preventing a comprehensive appraisal of less common but potentially serious events such as venous thromboembolism or malignancy, which are class concerns for JAK inhibitors.
  5. Single‑Study Basis: Approval rests on a single phase 3 trial; real‑world evidence and post‑marketing surveillance will be required to confirm effectiveness across diverse practice settings and to detect rare adverse outcomes.

In summary, the FDA’s approval of Lisraya marks a pivotal shift in the therapeutic landscape for adult dermatomyositis, providing the first oral, mechanism‑based option that improves disease activity and reduces reliance on systemic steroids. Ongoing data collection will be critical to define its long‑term safety profile and to explore its role in broader myopathy populations.